Clinical TrialMay 22, 2026, 06:07 AM
Perspective Therapeutics Reports Positive Interim Clinical Trial Data
AI Summary
Perspective Therapeutics announced positive interim results from its ongoing clinical trials for [212Pb]VMT01, [212Pb]PSV359, and [212Pb]VMT-α-NET, which will be presented at the 2026 ASCO Annual Meeting. The [212Pb]VMT01 melanoma trial observed a new responder, bringing total confirmed responses to 29% in the 3.0 mCi monotherapy cohort, with 86% showing stable disease or partial response. All three programs demonstrated good tolerability and safety profiles, with [212Pb]PSV359 advancing to Cohort 3 and [212Pb]VMT-α-NET showing continued deepening of responses and 72% of patients without progression.
Key Highlights
- Perspective Therapeutics reported one new responder in the [212Pb]VMT01 3.0 mCi monotherapy cohort for melanoma, totaling 2 of 7 patients (29%) with confirmed responses.
- In the [212Pb]VMT01 melanoma trial, 6 of 7 patients (86%) in the 3.0 mCi monotherapy cohort experienced stable disease or partial response.
- [212Pb]PSV359 for solid tumors advanced to Cohort 3; initial safety showed only Grades 1 and 2 TEAEs with no DLTs.
- Updated [212Pb]VMT-α-NET data for neuroendocrine tumors showed 18 of 25 patients (72%) were without progression and remained alive.
- For [212Pb]VMT-α-NET, 10 of 23 patients (43%) in Cohort 2 demonstrated investigator-assessed response.
- All three clinical programs ([212Pb]VMT-α-NET, [212Pb]VMT01, [212Pb]PSV359) were well-tolerated with no dose-limiting toxicities (DLTs).
Price Impact
More from CATX